[177Lu]FAPI-46

This study successfully demonstrated the reduction in FAP expression and suppression of tumor volume in sarcoma PDX following the combination therapy of 177Lu-FAPI-46 with Pazopanib.

FTV was greater than MTV (P < 0.05), but no significant differences were observed for the other parameters. Ga-FAPI-46 PET/CT showed good concordance and comparable diagnostic performance compared with F-FDG PET/CT for initial staging and recurrence detection in patients with HNSCC.

In this interim analysis of a prospective exploratory imaging trial, Ga-FAPi-46 PET biodistribution across multiple cancers strongly correlated with FAP tissue expression. These findings support further exploration of FAPi PET as a pan-cancer imaging biomarker for FAP expression and stratification tool for FAP- targeted therapies.

Purpose To evaluate the use of FAP inhibitor (FAPI) breast PET/MRI in assessing breast lesions and of FAPI whole-body scanning for lymph node (LN) and distant staging using the ligand gallium 68 (Ga)-FAPI-46..

This study suggested the possible application of FAPI radioligand therapy in FAP-expressing pancreatic cancer. Further evaluation is necessary to find the best radionuclide with shorter half-life, as well as the combination with therapies targeting tumour cells directly.

Low radiation doses to organs at risk suggest feasibility of repeat cycles of Y-FAPI-46. We observe signs of clinical activity, but further studies are warranted to determine efficacy and toxicity profile in a larger cohort.

Patients and PET-Scans of 15 patients with fILD and suspected LC were acquired 10, 60 and 180 minutes after the administration of 150-250 MBq of a Ga labelled FAPI tracer (FAPI-46)... FAPI-PET/CT imaging is a promising new imaging modality for fILD and LC. Its potential clinical value for monitoring and therapy evaluation of fILD should be investigated in future studies.

Novel radio-labelled FAP-Inhibitors (e.g. Ga-FAPI46) have shown high tumor uptake in positron emission tomography (PET) in sarcoma patients... We confirm an association of tumoral FAPI-PET uptake intensity and histopathological FAP expression in sarcoma patients. Further, using blinded reads and independent histopathological validation we report high PPV and sensitivity of FAPI-PET for sarcoma staging.

P1, N=30, Recruiting, Jonsson Comprehensive Cancer Center | Not yet recruiting --> Recruiting

P1, N=30, Recruiting, Jonsson Comprehensive Cancer Center | Not yet recruiting --> Recruiting

P1, N=30, Not yet recruiting, Jonsson Comprehensive Cancer Center

P1, N=30, Not yet recruiting, Jonsson Comprehensive Cancer Center